FindTrial
Sign In

Serum Free Light Change in Multiple Myeloma

Serum Free Light Chain Ratio, Total Kappa/Lambda Ratio, and Immunofixation as Prognostic Factors in Multiple Myeloma.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00910078
Enrollment
Unknown
Registered
2009-05-29
Start date
Unknown
Completion date
Unknown
Last updated
2009-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Keywords

Total kappa and lambda ratio, Stem cell transplantation, Serum immunofixation

Brief summary

The purpose of this study is to evaluate the predictive role of free Kappa/Lambda ration in Multiple Myeloma post-transplant.

Interventions

None listed

Sponsors

Azienda Ospedaliera San Giovanni Battista
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients affected with Multiple Myeloma who underwent autologous or auto/allogenic stem cell transplantation.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026